Completed PHASE1 INTERVENTIONAL 1-arm NCT01327911

Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)

A Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients With Macular Telangiectasia Type 2 (Mactel)

Sponsor: Neurotech Pharmaceuticals

Conditions Idiopathic Juxtafoveal Telangiectasia

Interventions NT-501 implant

Updated 6 times since 2017 Last updated: Nov 21, 2016 Started: May 31, 2011 Primary completion: Sep 30, 2016 Completion: Sep 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Idiopathic Juxtafoveal Telangiectasia and is currently completed. Neurotech Pharmaceuticals leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Neurotech Pharmaceuticals
The Lowy Medical Research Institute Limited

Data source: Neurotech Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States
• Los Angeles, United States